Enter to open, tab to navigate, enter to select
Antitrust risk-shifting provisions in Shire Pharmaceutical Holdings Ireland Limited/ViroPharma Incorporated tender offer
| November 11, 2013 • Antitrust Risk-shifting • $4.2 billion |
End of Document
© 2024 Thomson Reuters. No claim to original U.S. Government Works.